CA2687403A1 - Carbohydrate-containing pan cancer marker - Google Patents

Carbohydrate-containing pan cancer marker Download PDF

Info

Publication number
CA2687403A1
CA2687403A1 CA002687403A CA2687403A CA2687403A1 CA 2687403 A1 CA2687403 A1 CA 2687403A1 CA 002687403 A CA002687403 A CA 002687403A CA 2687403 A CA2687403 A CA 2687403A CA 2687403 A1 CA2687403 A1 CA 2687403A1
Authority
CA
Canada
Prior art keywords
antibody
igg
human
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002687403A
Other languages
English (en)
French (fr)
Inventor
Chi-Yu Gregory Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vancouver Biotech Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687403A1 publication Critical patent/CA2687403A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002687403A 2007-05-14 2008-05-14 Carbohydrate-containing pan cancer marker Abandoned CA2687403A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91790607P 2007-05-14 2007-05-14
US60/917,906 2007-05-14
US4402808P 2008-04-10 2008-04-10
US61/044,028 2008-04-10
PCT/CA2008/000932 WO2008138139A1 (en) 2007-05-14 2008-05-14 Carbohydrate-containing pan cancer marker

Publications (1)

Publication Number Publication Date
CA2687403A1 true CA2687403A1 (en) 2008-11-20

Family

ID=40001646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002687403A Abandoned CA2687403A1 (en) 2007-05-14 2008-05-14 Carbohydrate-containing pan cancer marker

Country Status (7)

Country Link
US (2) US8143373B2 (enExample)
EP (1) EP2155250B1 (enExample)
JP (1) JP5683948B2 (enExample)
CN (1) CN102014955A (enExample)
AU (1) AU2008250953B2 (enExample)
CA (1) CA2687403A1 (enExample)
WO (1) WO2008138139A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006718A1 (en) * 2010-07-14 2012-01-19 Vancouver Biotech Ltd. Carbohydrate hapten-based anti-cancer vaccines and antibody drugs
CN102901817A (zh) * 2011-07-27 2013-01-30 北京大学 Non-B Ig单抗RP215在细胞增殖、迁移及干细胞研究中的应用
US8974786B2 (en) * 2012-06-13 2015-03-10 Vancouver Biotech Ltd. Humanized antibodies to CA215
CN105353132B (zh) * 2015-11-13 2018-04-10 北京大学 non B‑s IgG作为干/祖细胞标志物的应用
CA3048312A1 (en) 2017-01-01 2018-07-05 Chi-Yu Gregory Lee Rp215 chimeric antigen receptor construct and methods of making and using same
CN108484777B (zh) * 2017-03-31 2022-07-12 李吉祐 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991002079A1 (en) * 1989-07-31 1991-02-21 The University Of British Columbia Monoclonal antibodies against a tumor-associated antigen
US6312924B1 (en) * 1999-03-18 2001-11-06 Zymogenetics, Inc. Murine interferon-α
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
PL371202A1 (en) * 2002-04-09 2005-06-13 Merck Patent Gmbh Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
US20080081045A1 (en) * 2003-10-14 2008-04-03 Biomira, Inc. Combination Therapy for Cancer

Also Published As

Publication number Publication date
US20120177636A1 (en) 2012-07-12
WO2008138139A1 (en) 2008-11-20
AU2008250953A2 (en) 2011-02-10
AU2008250953A1 (en) 2008-11-20
US8143373B2 (en) 2012-03-27
EP2155250B1 (en) 2015-04-15
JP2010529950A (ja) 2010-09-02
US20110033445A1 (en) 2011-02-10
EP2155250A1 (en) 2010-02-24
JP5683948B2 (ja) 2015-03-11
AU2008250953B2 (en) 2013-10-31
CN102014955A (zh) 2011-04-13
EP2155250A4 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
US12453780B2 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
US12180296B2 (en) Cross species single domain antibodies targeting mesothelin for treating solid tumors
US10941211B2 (en) Anti-GCC antibody molecules and related compositions and methods
AU2011200789B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
US12122843B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
US9738726B2 (en) HER2-specific monoclonal antibodies and conjugates thereof
EA027887B1 (ru) Конъюгаты антитело-лекарственное средство, связывающиеся с белками 191p4d12
AU2018268970B2 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
CN104059150A (zh) 结合epha2的抗体及其使用方法
AU2008250953B2 (en) Carbohydrate-containing pan cancer marker
KR20040010613A (ko) 항암 항체
CN114650843A (zh) 包括fc突变和位点特异性缀合性质的抗体组合物
US20230032465A1 (en) Antibody-drug conjugates specific for cd276 and uses thereof
TWI904701B (zh) 抗ceacam5/6雙結合抗體
CN121941709A (zh) 抗cdh17抗体-药物偶联物及其制备和使用方法
CN119403830A (zh) 抗cd200r1抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130509

FZDE Discontinued

Effective date: 20170201